Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Atherosclerosis
1 Circ Genom Precis Med
3 Circulation
1 Int J Cardiol
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
    SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
    Atherosclerosis. 2020;306:41-49.
    PubMed         Abstract available

    Circ Genom Precis Med

  2. RIPATTI P, Rama JT, Mars NJ, Fu Y, et al
    Polygenic Hyperlipidemias and Coronary Artery Disease Risk.
    Circ Genom Precis Med. 2020 Mar 10. doi: 10.1161/CIRCGEN.119.002725.
    PubMed         Abstract available


  3. KHERA AV, Hegele RA
    What Is Familial Hypercholesterolemia, and Why Does It Matter?
    Circulation. 2020;141:1760-1763.

  4. HOVINGH GK, Lepor NE, Kallend D, Stoekenbroek RM, et al
    Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Circulation. 2020;141:1829-1831.

  5. HU P, Dharmayat KI, Stevens CAT, Sharabiani MTA, et al
    Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
    Circulation. 2020 May 29. doi: 10.1161/CIRCULATIONAHA.119.044795.

    Int J Cardiol

  6. HAN J, Bilgrami S, Ross S, Broadhead H, et al
    Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study.
    Int J Cardiol. 2021;322:240-244.

    PLoS One

  7. WONG JC, O'Neill S, Beck BR, Forwood MR, et al
    Comparison of obesity and metabolic syndrome prevalence using fat mass index, body mass index and percentage body fat.
    PLoS One. 2021;16:e0245436.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.